Project Grant R43AI186917
Award Date 8/24/26
Completion Date 7/31/28
Dollars Obligated $303K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Framingham, MA 01702, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Baylor College of Medicine $191,219 under grant K23AI199607 on June 2, 2026, to conduct an epidemiological assessment of Strongyloides stercoralis infection in at-risk populations in Texas. The funded research aims to understand the epidemiology and risk factors of strongyloidiasis in the greater Houston metropolitan area through two primary objectives. The first objective determines chronic strongyloidiasis prevalence and...
- The National Institute of Allergy and Infectious Diseases awarded Helixbind, Inc. $1,029,859 on July 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance development of an automated molecular diagnostic system for rapid characterization of bloodstream infections directly from whole blood. Helixbind is developing a sample-to-answer assay that identifies pathogens causing sepsis and antimicrobial-resistant organisms within approximately four hours,...
- The National Institute of Allergy and Infectious Diseases awarded L2 Diagnostics LLC $567,852 on September 21, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a rapid diagnostic test for Babesia microti infection. L2 Diagnostics is developing a point-of-care lateral flow assay that detects BMGPI12 (BMSA1), a secreted protein expressed by the Babesia parasite during active infection. The test is intended for use by physicians at the point of patient...
- The National Institute of Allergy and Infectious Diseases awarded Impact Proteomics LLC $320,863 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to establish clinical and technical feasibility of an immunoproteomics diagnostic platform for autoimmune disease detection and monitoring. Impact Proteomics will develop and validate an IP-to-mass spectrometry (IP-to-MS) workflow that leverages a patented PromTag system to separate autoantigens from...
- The National Institute of Allergy and Infectious Diseases awarded L2 Diagnostics LLC $599,954 on September 15, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop PFAG, a multivalent peptide vaccine against malaria. The project, designated Phase I STTR, optimizes a prototype vaccine construct composed of short synthetic peptides representing specific immunogenic epitopes of the Plasmodium falciparum circumsporozoite (CSP) and Anopheles gambiae trio (AG trio)...
- The National Institute of Allergy and Infectious Diseases awarded Abterra Biosciences, Inc. $306,555 on August 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a serum antibody repertoire analysis platform for diagnosing systemic lupus erythematosus. Abterra will develop CDR3-SEQ, a novel technology platform that profiles over 1,000 antibody sequences from serum by analyzing the complementarity determining region 3 (CDRH3), the key domain for...
- The National Institute of Allergy and Infectious Diseases awarded Peak Diagnostic Partners Inc. one million dollars on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R44AI186802. The award funds a multidimensional analysis of biologic treatment failure in uncontrolled asthma. The research addresses the challenge that up to 50% of asthma patients treated with biologic therapies experience suboptimal response or deterioration despite...
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
- Federal Grant Award Summary Kephera Diagnostics LLC received a $470,013 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with a completion date of August 31, 2028. The award supports development of a peptide-based enzyme-linked immunosorbent assay (ELISA) diagnostic test for sarcoidosis, a systemic inflammatory disease affecting approximately 200,000 patients in the...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded The University of Texas Southwestern Medical Center $192,369 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define CD4+ T-cell populations driving protection and susceptibility in hookworm reinfection. The research will characterize immune mechanisms that prevent parasite clearance in chronic helminth infections, with direct applications to prevention, diagnosis, and...